azacitidine has been researched along with nelarabine in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Hochhaus, A; Kunert, C; Schnetzke, U; Scholl, S; Schrenk, K; Spies-Weisshart, B | 1 |
1 review(s) available for azacitidine and nelarabine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 other study(ies) available for azacitidine and nelarabine
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Different clones of acute leukemia after successful treatment of Hodgkin's disease.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Azacitidine; Bleomycin; Bone Marrow; Clone Cells; Consolidation Chemotherapy; Dacarbazine; Doxorubicin; Fatal Outcome; Female; fms-Like Tyrosine Kinase 3; Hodgkin Disease; Humans; Immunophenotyping; Leukemia, Myelomonocytic, Acute; Neoplasm Proteins; Neoplasms, Second Primary; Neoplastic Stem Cells; Palliative Care; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Remission Induction; Salvage Therapy; Vinblastine | 2014 |